Inositec
Z├╝rich
About Inositec
Inositec is a biotech company that develops a treatment for soft tissue calcification disorders based on its proprietary Inositune platform of inositol phosphate (IP6) analogs. Its lead programs address vascular and renal calcification disorders, including orphan indications. The company was founded in 2015 as a spin-off of ETH Zurich.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.4M
- Funding stage: M&A
- Last round: Seed (Oct 2016)
- Website: inositec.com
- Phone: +41442710755
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/inositec-203078 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.